Head to Head Analysis: Immix Biopharma (NASDAQ:IMMX) & Athira Pharma (NASDAQ:ATHA)

Athira Pharma (NASDAQ:ATHA) and Immix Biopharma (NASDAQ:IMMX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Insider & Institutional Ownership

57.1% of Athira Pharma shares are held by institutional investors. Comparatively, 11.3% of Immix Biopharma shares are held by institutional investors. 22.1% of Athira Pharma shares are held by company insiders. Comparatively, 55.4% of Immix Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Athira Pharma and Immix Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Athira Pharma	N/A	-107.06%	-89.89%
Immix Biopharma	N/A	-263.56%	-119.99%

Valuation and Earnings

This table compares Athira Pharma and Immix Biopharma”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athira Pharma	N/A	N/A	-$96.94 million	($9.68)	-0.75
Immix Biopharma	N/A	N/A	-$21.61 million	($0.77)	-7.56

Immix Biopharma is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Athira Pharma has a beta of 2.95, indicating that its share price is 195% more volatile than the S&P 500. Comparatively, Immix Biopharma has a beta of 0.33, indicating that its share price is 67% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings for Athira Pharma and Immix Biopharma, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athira Pharma	1	0	0	0	1.00
Immix Biopharma	1	1	1	0	2.00

Athira Pharma currently has a consensus price target of $4.00, suggesting a potential downside of 45.13%. Immix Biopharma has a consensus price target of $8.00, suggesting a potential upside of 37.36%. Given Immix Biopharma’s stronger consensus rating and higher probable upside, analysts plainly believe Immix Biopharma is more favorable than Athira Pharma.

Summary

Immix Biopharma beats Athira Pharma on 6 of the 11 factors compared between the two stocks.

About Athira Pharma

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.

About Immix Biopharma

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.